Six-month efficacy and safety of oxymetazoline hydrochloride 0.1% in Japanese patients with acquired blepharoptosis: a phase 3 study
Ishikawa H., Oka K., Inoue H.
Dedicated to scientific advancement and pioneering discoveries in ophthalmology
As a specialist with over 130 years of expertise, Santen is committed to continually investigating the latest in science and innovation to deliver the best vision experience.
About Publications PlusBrowse Publications
Therapeutic Area
Technology
Category
Latest Publications
Tear Biomarkers of Topical Sirolimus in Meibomian Gland Dysfunction: A Randomized Trial
Zhou L.; Shimizu H.; Togashi Y.; Kirihara T.; Yang Y.; Lam C.T.; Shimada H.; Tong L.
STudy of Atropine to Reduce (STAR) Myopia Progression in Children: 24‑Month Results of a Randomized, Double‑Masked, Vehicle‑Controlled Trial of Atropine Sulfate 0.01% and 0.03%
Korenfeld M.; Hurcikova M.; Tatsuoka K.; Cheetham J.; Kacerik M.; on behalf of the STAR Study Investigators